Venom-Derived Drug Trial Gets FDA OK

Xconomy Boston — 

Transmolecular, a Cambridge, MA-based biotech firm, reports that the FDA has agreed to consider a filing for approval of its lead anti-cancer drug (TM601) if the molecule meets goals of a late-stage clinical trial, under the agency’s so-called Special Protocol Assessment process. The trial will test the molecule—derived from yellow scorpion venom—as a treatment for patients with lethal brain tumors called glioblastoma multiforme.